Page last updated: 2024-11-07

propranolol glucuronide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID119515
CHEBI ID186175
MeSH IDM0077673

Synonyms (14)

Synonym
propranolol glucuronide
(2s,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-yl]oxyoxane-2-carboxylic acid
CHEBI:186175
66322-66-5
unii-64cg9re9h6
64cg9re9h6 ,
beta-d-glucopyranosiduronic acid, 1-(((1-methylethyl)amino)methyl)-2-(1-naphthalenyloxy)ethyl
propranolol-2-o-b-d-glucuronide
W-203454
propranolol glucuronide sodium salt
1-[(naphthalen-1-yl)oxy]-3-[(propan-2-yl)amino]propan-2-yl hexopyranosiduronic acid
DTXSID30984920
.beta.-d-glucopyranosiduronic acid, 1-(((1-methylethyl)amino)methyl)-2-(1-naphthalenyloxy)ethyl
propranolol glucuronide, (+/-)-

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The method is applied to pharmacokinetic studies of racemic propranolol in human plasma and urine."( Microassay of propranolol enantiomers and conjugates in human plasma and urine by high-performance liquid chromatography after chiral derivatization for pharmacokinetic study.
Claude, JR; Ellouk-Achard, S; Fompeydie, D; Galons, H; Gramond, JP; Levresse, V; Pham-Huy, C; Saada, V; Sahui-Gnassi, A, 1994
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
glucosiduronic acidAny substance produced by linking glucuronic acid to another substance via a glycosidic bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Propranolol Pathway, Pharmacokinetics95

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (46.15)18.7374
1990's3 (23.08)18.2507
2000's4 (30.77)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.38 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (12.50%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]